Deucravacitinib is a tyrosine kinase 2 inhibitor currently being investigated for use in the treatment of psoriatic arthritis and in a long-term extension trial for psoriasis. It was a pleasure to talk with Prof. Roy Fleischmann (University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, USA) to learn more around the findings from his analysis assessing the safety of deucravacitinib in psoriasis and psoriatic arthritis.
The abstract ‘Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor: As Assessed by Laboratory Parameters – Results From a Phase 2 Trial in Psoriatic Arthritis and 2 Phase 3 Trials in Psoriasis.’ (Abstract number: POS1040) was presented at the European Congress of Rheumatology 2022, 1-4 June, 2022.
- What is deucravacitinib and what is its mechanism of action? (0:17)
- What have clinical trials to date taught us about the efficacy and safety of deucravacitinib in psoriasis and psoriatic arthritis? (1:06)
- What were the objectives of the analysis presented at EULAR and what parameters were assessed? (2:15)
- What were the findings of the analysis and how do they compare with other disease-modifying antirheumatic drugs? (3:13)
- Where do you see deucravacitinib potentially sitting in the treatment paradigm for psoriasis and psoriatic arthritis? (4:29)
Disclosures: Roy Fleischmann discloses consulting for and receiving clinical trial grants from BMS.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EULAR meeting 2022.
Share this Video
Related Videos In Psoriatic Arthritis
Laure Gossec, EULAR 2022: Guselkumab for Psoriatic Arthritis – An Analysis of the Phase 3b COSMOS Trial
The Phase 3b COSMOS trial (ClinicalTrials.gov Identifier: NCT03796858) investigated guselkumab in patients with psoriatic arthritis that had an inadequate response to anti-tumor necrosis factor alpha (Anti-TNF Alpha) therapy. We were delighted to speak to Professor Laure Gossec (Pitie-Salpetriere Hospital and Sorbonne Universite, Paris, France) to discuss the findings from her analysis of the phase 3b […]
Xenofon Baraliakos, EULAR 2022: Upadacitinib in the Treatment of Psoriatic Arthritis with Axial Involvement
Upadacitinib is an oral JAK1 inhibitor approved for the treatment of psoriatic arthritis. It was a pleasure to talk with Prof. Xenofon Baraliakos (Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany) about the impact of axial involvement on patients with psoriatic arthritis and the findings from his study investigating upadacitinib in the treatment of PsA with axial […]
Roy Fleischmann, EULAR 2022: Deucravacitinib a Tyrosine Kinase 2 Inhibitor for Psoriasis and Psoriatic Arthritis
Deucravacitinib is a tyrosine kinase 2 inhibitor currently being investigated for use in the treatment of psoriatic arthritis and in a long-term extension trial for psoriasis. It was a pleasure to talk with Prof. Roy Fleischmann (University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, USA) to learn more around the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!